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Chronic myelogenous leukemia is a myeloproliferative disorder characterized by the t(9:22) 
(q34:q11) reciprocal chromosomal translocation, resulting in the expression of the chimeric Bcr–
Abl oncoprotein with constitutive tyrosine kinase activity. Deregulated Bcr–Abl induces the 
hyperactivation of various signalling pathways that promote cell growth, suppress apoptosis and 
alter cell adhesion. Bcr-Abl has also been involved in VEGF-mediated angiogenesis in CML and 
evidence indicates that the formation of new vessels plays an important role in the development 
and progression of CML. Imatinib mesylate (IM) is a selective well tolerated inhibitor of the Bcr–
Abl tyrosine kinase that has significantly improved the prognosis of patients with chronic phase 
CML. Despite this remarkable progress, a major problem associated with the administration of 
imatinib is acquired resistance. Bcr-Abl gene amplification, increased expression of Bcr–Abl 
protein, point mutations in the Bcr–Abl tyrosine kinase domain have been reported as 
mechanisms of resistance to imatinib. Therefore, there is an urgent need for new anticancer 
agents and combinations that could improve responses and survival rates for CML. Recent studies 
from our laboratory have shown that addition of carboxyamidotriazole (CAI), an inhibitor of 
calcium-mediated signal transduction, to imatinib resistant human CML cells induces a marked 
decrease in cell viability and augmented apoptosis, events associated with downregulation of 
Bcr–Abl protein and inhibition of tyrosine phosphorylation of Bcr–Abl, STAT5, CrkL. 
Carboxyamidotriazole Orotate (CTO), is a derivate of CAI that has been developed at Tactical 
Therapeutics. CTO has a higher bioavailability and efficacy with respect to the parental 
compound. Exosomes are small vesicles of 40-100 nm diameter that are initially formed within 
the endosomal compartment and are secreted when a multivesicular body (MVB) fuses with the 
plasma membrane. These vesicles are released by many cell types including cancer cells and are 
considered messengers in intercellular communication. The exact function of exosomes in 
malignant cells has yet to be elucidated, but investigation has suggested roles in cell-to-cell 
communication, tumor-stroma interaction, and antigen presentation, thus potentially affecting 
cancer progression at different steps. Recent studies from our laboratory suggest that exosomes 
released from IM-sensitive CML cells directly affect endothelial cells modulating the process of 
neovascularization. Our data show that CTO is able to inhibit both in vitro and in vivo the growth 
of imatinib-resistant CML cells and to affect tumor microenvironment by modulating exosome-
stimulated angiogenesis. CTO may be effective in targeting both cancer cell growth and the tumor 
microenvironment, thus suggesting a potential therapeutic utility in the treatment of leukemia 
patients. 
 
 
